From Rituals to Medicine: Therapeutic Potential and Ethical Challenges of Hallucinogens

Cordell GA. Alkaloids: Chemical & Biological Perspectives, Vol. 11 Edited by S. William Pel- letier (University of Georgia). Elsevier Science, New York, NY. 1996. xvii + 393 pp. 15 × 22.5 cm. $190.00. ISBN: 0-08-042797-9. J Nat Prod. 1997 Sep 1;60(9):954-5. doi:10.1021/np970082d

Kaur R, Arora S. Alkaloids-important therapeutic secondary metabolites of plant origin. J Crit Rev. 2015;2(3):1-8.

Sireesha B, Reddy BV, Basha SK, Chandra K, Anasuya D, Bhavani M. A review on pharmaco- logical activities of alkaloids. World J Curr Med Pharm Res. 2019;1:230-4.

Debnath B, Singh WS, Das M, Goswami S, Singh MK, Maiti D, et al. Role of plant alkaloids on human health: A review of biological activities. Materials today chemistry. 2018;9:56-72.

Kumar A. Plant alkaloids. In: Phytoconstituents and Antifungals [Internet]. Elsevier; 2022 [cit- ed 2025 Mar 17]. p. 53-64. Available from: https://www.sciencedirect.com/science/article/pii/ B9780323917926000091

Fisher R. Overview of Psychedelics: Nomenclature, Effects and Mechanisms of Action [Inter- net]. 2021 [cited 2025 Mar 17]. Available from: https://medicalcannabisprimer.com/images/ stories/blog/overview_psychedelics/Fisher_Overview_of_Psychedelics.pdf

Levine BS, Kerrigan S, editors. Principles of Forensic Toxicology [Internet]. Cham: Spring- er International Publishing; 2020 [cited 2025 Mar 17]. Available from: http://link.springer. com/10.1007/978-3-030-42917-1 doi:10.1007/978-3-030-42917-1

Bogenschutz MP, Ross S. Therapeutic Applications of Classic Hallucinogens. In: Halber- stadt AL, Vollenweider FX, Nichols DE, editors. Behavioral Neurobiology of Psychedelic Drugs [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2016 [cited 2025 Mar 17].p. 361-91. (Current Topics in Behavioral Neurosciences). Available from: http://link.springer. com/10.1007/7854_2016_464 doi:10.1007/7854_2016_464

Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psy- chopharmacol. 2008 Aug;22(6):603-20. doi:10.1177/0269881108093587

Cohen S. The Use of LSD in Psychotherapy and Alcoholism| Edited by Harold A. Abramson, MD Indianapolis: Bobbs Merrill, 1967. 697 pages. $17.50. Elsevier; 1967.

Nichols DE. Hallucinogens. Pharmacol Ther. 2004 Feb;101(2):131-81. doi:10.1016/j. pharmthera.2003.11.002 PubMed PMID: 14761703.

Osmond H. A REVIEW OF THE CLINICAL EFFECTS OF PSYCHOTOMIMET- IC AGENTS. Annals of the New York Academy of Sciences. 1957 Mar;66(3):418-34. doi:10.1111/j.1749-6632.1957.tb40738.x

Cody JT. Chapter 4 Hallucinogens. In: Bogusz MJ, editor. Handbook of Analytical Separa- tions [Internet]. Elsevier Science B.V.; 2008 [cited 2025 Mar 17]. p. 175-201. (Forensic Sci- ence). Available from: https://www.sciencedirect.com/science/article/pii/S1567719206060049 doi:10.1016/S1567-7192(06)06004-9

14. Nichols DE. Psychedelics. Pharmacol Rev. 2016 Apr;68(2):264-355. doi:10.1124/pr.115.011478 PubMed PMID: 26841800; PubMed Central PMCID: PMC4813425.

Schultes RE, Hofmann A. Plants of the gods: their sacred, healing, and hallucinogenic powers. [Internet]. 1992 [cited 2025 Mar 17]. Available from: https://agris.fao.org/search/en/provid- ers/123819/records/64735d8308fd68d546030f63

Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience. 2010;11(9):642-51.

Dos Santos RG, Osório FL, Crippa JAS, Riba J, Zuardi AW, Hallak JEC. Antidepressive, anxio- lytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology. 2016 Jun;6(3):193-213. doi:10.1177/2045125316638008

Hermle L, Fünfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, et al. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: exper- imental psychosis as a tool for psychiatric research. Biological psychiatry. 1992;32(11):976-91.

Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study of N, N-dimeth- yltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Archives of general psychiatry. 1994;51(2):98-108.

Strassman RJ, Qualls CR. Dose-response study of N, N-dimethyltryptamine in humans:

Neuroendocrine, autonomic, and cardiovascular effects. Archives of general psychiatry. 1994;51(2):85-97.

Stolaroff M. The secret chief revealed: conversations with a pioneer of the underground therapy movement. Sarasota: Multidisciplinary Association for Psychedelic Studies. 2004.

Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psycho- pharmacol. 2011 Nov;25(11):1434-52. doi:10.1177/0269881110382466

Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. The lancet. 2013;382(9904):1575-86.

Insel TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, et al. Innovative solu- tions to novel drug development in mental health. Neuroscience & Biobehavioral Reviews. 2013;37(10):2438-44.

Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiat- ric disorders: psilocybin and MDMA. The Lancet Psychiatry. 2016;3(5):481-8.

Brielmann HL, Setzer WN, Kaufman PB, Kirakosyan A, Cseke LJ. Phytochemicals: The chem- ical components of plants. Natural products from plants. 2006;2:1-49.

Croteau R, Kutchan TM, Lewis NG. Natural products (secondary metabolites). Biochemistry and molecular biology of plants. 2000;24:1250-319.

Pelletier SW, editor. Alkaloids: Chemical and Biological Perspectives [Internet]. New York, NY: Springer New York; 1991 [cited 2025 Mar 17]. Available from: http://link.springer. com/10.1007/978-1-4612-3006-9 doi:10.1007/978-1-4612-3006-9

Roy A. A review on the alkaloids an important therapeutic compound from plants. IJPB. 2017;3(2):1-9.

Ashutosh K. Pharmacognosy and pharmacobiotechnology. New Age International (P) Ltd, Publishers, New Delhi. 2007;396(398,464,465).

Svendsen A, Verpoorte R. Book Review: Chromatography of Alkaloids. Part A: Thin-Layer Chromatography. J Nat Prod. 1984 Nov;47(6):1069-1069. doi:10.1021/np50036a048

Aniszewski T. Alkaloids-secrets of life:: Aklaloid chemistry, biological significance, applica- tions and ecological role [Internet]. Elsevier; 2007 [cited 2025 Mar 17]. Available from: https:// books.google.com/books?hl=tr&lr=&id=a1Z6oJL-dgMC&oi=fnd&pg=PP1&dq=Aniszews- ki+T.+Alkaloids+-+secrets+of+life:+Aklaloid+chemistry,+biological+significance,+applicat- ions+and+ecological+role,+Elsevier.+Netherlands,+2007+DOI:10.1016/B978-0-444-52736-3. X5000-4.&ots=Ms7fk0RnIy&sig=14bnoGp3xMqNJl5_IkcJHJKgP20

Funayama S, Cordell GA. Alkaloids: a treasury of poisons and medicines [Internet]. Else- vier; 2014 [cited 2025 Mar 17]. Available from: https://books.google.com/books?hl=tr&l- r=&id=xMs6BAAAQBAJ&oi=fnd&pg=PP1&dq=Funayama+S,+Cordell+GA.+Alka- loids:+A+Treasury+of+Poisons+and+Medicines.+Elsevier+Inc.,+2014+DOI:10.1016/ C2012-0-07416-9.&ots=D7HKslaeUP&sig=xNlnVL0pjJpPQsR3CglwZ2X5OE0

Roberts MF. Alkaloids: biochemistry, ecology, and medicinal applications [Internet]. Spring- er Science & Business Media; 2013 [cited 2025 Mar 17]. Available from: https://books.google. com/books?hl=tr&lr=&id=TMEGCAAAQBAJ&oi=fnd&pg=PA1&dq=Alkaloids:Biochemis- try,ecology+and+medicinal+applications.+New+York,+1998.&ots=p7z3bVnRMr&sig=eHsu_ svB-pbGl6cq4arI33D3zyk

Heinrich M. Ethnopharmacology and drug discovery. Comprehensive Natural Products II: Chemistry and Biology, Development & Modification of Bioactivity. 2013;3:351-81.

Salminen KA, Meyer A, Jerabkova L, Korhonen LE, Rahnasto M, Juvonen RO, et al. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. Phy- tomedicine. 2011;18(6):533-8.

Tanker M, Tanker N. Farmakognozi. Ankara Üniversitesi Eczacılık Fakültesi Yayınları. 1990;65(2):301-2.

Ziegler J, Facchini PJ. Alkaloid Biosynthesis: Metabolism and Trafficking. Annu Rev Plant Biol. 2008 Jun 1;59(1):735-69. doi:10.1146/annurev.arplant.59.032607.092730

Marella A, Tanwar OP, Saha R, Ali MR, Srivastava S, Akhter M, et al. Quinoline: A versatile heterocyclic. Saudi Pharmaceutical Journal. 2013;21(1):1-12.

Frick S, Kramell R, Schmidt J, Fist AJ, Kutchan TM. Comparative Qualitative and Quantitative Determination of Alkaloids in Narcotic and Condiment Papaver s omniferum Cultivars. J Nat Prod. 2005 May 1;68(5):666-73. doi:10.1021/np0496643

Reynolds CD, Palmer RA, Gorinsky B. Crystal and molecular structure of the alkaloid pa- paverine hydrochloride. Journal of Crystal and Molecular Structure. 1974 Jul;4(4):213-25. doi:10.1007/BF01198178

Shimizu K, Yoshihara E, TAKAHASHI M, Gotoh K, Orita S, Urakawa N, et al. Mechanism of relaxant response to papaverine on the smooth muscle of non-pregnant rat uterus. Journal of Smooth Muscle Research. 2000;36(3):83-91.

Herman A, Herman AP. Caffeine’s mechanisms of action and its cosmetic use. Skin pharmacol- ogy and physiology. 2012;26(1):8-14.

Li S, Lo CY, Pan MH, Lai CS, Ho CT. Black tea: chemical analysis and stability. Food & function. 2013;4(1):10-8.

Singh AK, Chawla R, Rai A, Yadav LDS. NHC-catalysed diastereoselective synthesis of multi- functionalised piperidines via cascade reaction of enals with azalactones. Chemical Communi- cations. 2012;48(31):3766-8.

Machado PA, Hilário FF, Carvalho LO, Silveira MLT, Alves RB, Freitas RP, et al. Effect of 3‐Al- kylpyridine Marine Alkaloid Analogues in Leishmania Species Related to American Cutaneous Leishmaniasis. Chem Biol Drug Des. 2012 Nov;80(5):745-51. doi:10.1111/cbdd.12017

Cronemberger S, Calixto N, Moraes MN, Castro ID, Lana PC, Loredo AF. Efficacy of one drop of 2% pilocarpine to reverse the intraocular pressure peak at 6: 00 am in early glaucoma. The Pan-American Journal of Ophthalmology. 2012;11(1):14-6.

Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, et al. Pharma- cological effects of ephedrine alkaloids on human α1-and α2-adrenergic receptor subtypes. The Journal of pharmacology and experimental therapeutics. 2007;322(1):214-21.

Abraham HD, Aldridge AM, Gogia P. The psychopharmacology of hallucinogens. Neuropsy- chopharmacology. 1996;14(4):285-98.

LE H. CHEMICAL PSYCHOSES. Annual Review of Medicine. 1964;15:203-14.

Kaplan RM. Humphry Fortescue Osmond (1917-2004), a radical and conventional psychiatrist: The transcendent years. J Med Biogr. 2016 Feb;24(1):115-24. doi:10.1177/0967772013479520

Canal CE, Murnane KS. The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens. J Psychopharmacol. 2017 Jan;31(1):127-43. doi:10.1177/0269881116677104

Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics. Current Biology. 2022 Jan 24;32(2):R63-7. doi:10.1016/j.cub.2021.12.009 PubMed PMID: 35077687.

Ray TS. Psychedelics and the Human Receptorome. PLOS ONE. 2010 Feb 2;5(2):e9019. doi:10.1371/journal.pone.0009019

Nichols DE. Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens. Journal of Psychoactive Drugs. 1986 Oct;18(4):305-13. doi:10.1080/02791072.1986.10472362

Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non‐medical use of dissociative drugs. Drug Testing and Analysis. 2014 Jul;6(7-8):614-32. doi:10.1002/dta.1620

Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: A review. Ex- perimental and Clinical Psychopharmacology. 2016;24(4):229-68. doi:10.1037/pha0000084

Keeler MH, Ewing JA, Rouse BA. Hallucinogenic Effects of Marijuana as Currently Used. AJP. 1971 Aug;128(2):213-6. doi:10.1176/ajp.128.2.213

Hofmann A. LSD: My Problem Child: Reflections on Sacred Drugs, Mysticism, and Science. First Edition. J.P. Tarcher, Inc.; 1983. 202 p.

Jeremy Ott J. Teonanácatl: Hallucinogenic Mushrooms of North America. Seattle: Madrona Publishers; 1978. 175 p.

Dobkin De Rios M. Ayahuasca—The Healing Vine. Int J Soc Psychiatry. 1971 Dec;17(4):256- 69. doi:10.1177/002076407101700402

Hofmann A. How LSD Originated. Journal of Psychedelic Drugs [Internet]. 1979 Jan 1 [cited 2025 Mar 18]. Located at: world. Available from: https://www.tandfonline.com/doi/abs/10.108 0/02791072.1979.10472092

Hofmann A, Heim R, Brack A, Kobel H, Frey A, Ott H, et al. Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen. Helvetica Chimica Acta. 1959 Jan;42(5):1557-72. doi:10.1002/hlca.19590420518

Grinspoon L, Bakalar JB. The psychedelic drug therapies. Curr Psychiatr Ther. 1981 Jan 1;20:275-83. PubMed PMID: 7326971.

Butts JD. Altered States of Consciousness. J Natl Med Assoc. 1978 Oct;70(10):743-4. PubMed PMID: 712866; PubMed Central PMCID: PMC2537105.

Chan RHA, Mendelson JE. Chapter Seventeen - Hallucinogens. In: Madras B, Kuhar M, editors. The Effects of Drug Abuse on the Human Nervous System [Internet]. Boston: Academic Press; 2014 [cited 2025 Mar 18]. p. 533-52. Available from: https://www.sciencedirect.com/science/ article/pii/B9780124186798000174 doi:10.1016/B978-0-12-418679-8.00017-4

Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci. 2013 Aug;14(8):577-85. doi:10.1038/nrn3530

B. Liester M. A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addic- tions: Historical Perspectives and Future Prospects. Current Drug Abuse Reviews. 2014 Dec 1;7(3):146-56.

Oram M. Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962. Journal of the History of Medicine and Allied Sciences. 2014 Apr 1;69(2):221-50. doi:10.1093/ jhmas/jrs050

Krebs TS, Johansen PØ. Psychedelics and Mental Health: A Population Study. PLOS ONE. 2013 Aug 19;8(8):e63972. doi:10.1371/journal.pone.0063972

Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occa- sioned mystical-type experiences: immediate and persisting dose-related effects. Psychophar- macology. 2011 Dec;218(4):649-65. doi:10.1007/s00213-011-2358-5

Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type expe- riences having substantial and sustained personal meaning and spiritual significance. Psycho- pharmacology. 2006 Aug 1;187(3):268-83. doi:10.1007/s00213-006-0457-5

Woolley DW. Production of abnormal (psychotic?) behavior in mice with lysergic acid dieth- ylamide, and its partial prevention with cholinergic drugs and serotonin. Proc Natl Acad Sci USA. 1955 Jun 15;41(6):338-44. doi:10.1073/pnas.41.6.338

Halpern JH, Pope HG. Do hallucinogens cause residual neuropsychological toxicity? Drug and Alcohol Dependence. 1999 Feb 1;53(3):247-56. doi:10.1016/S0376-8716(98)00129-X

Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochemical Pharmacology. 2008 Jan 1;Addiction Special Issue75(1):17-33. doi:10.1016/j. bcp.2007.07.018

Hofmann A. Historical view on ergot alkaloids. Pharmacology. 1978;16 Suppl 1:1-11. doi:10.1159/000136803 PubMed PMID: 347462.

Hradilová M, Vrabka J, Vanková V, Galuszka P. Ergot alkaloid production in Claviceps pur- purea is regulated by tryptophan related genes. New Biotechnology. 2018 Oct 1;44:S115. doi:10.1016/j.nbt.2018.05.1026

Petersen M, Garg U, Ketha H. Hallucinogens—psychedelics and dissociative drugs. In. 2020. p. 295-303. doi:10.1016/B978-0-12-815846-3.00016-8

Tasker NR, Wipf P. Biosynthesis, total synthesis, and biological profiles of Ergot alkaloids. Al- kaloids Chem Biol. 2021;85:1-112. doi:10.1016/bs.alkal.2020.08.001 PubMed PMID: 33663751.

Holloway K. The Secret Black History of LSD [Internet]. 2022 Mar 22 [cited 2025 Mar 18]. Available from: https://www.thenation.com/article/society/lsd-acid-black-history/

Ladewig D, Pletscher A. Fifty Years of LSD: Current Status and Perspectives of Hallucinogens. CRC Press; 1994. 250 p.

Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lyser- gic acid diethylamide: a review. CNS Neurosci Ther. 2008;14(4):295-314. doi:10.1111/j.1755- 5949.2008.00059.x PubMed PMID: 19040555; PubMed Central PMCID: PMC6494066.

Hovda LR, Brutlag AG, Poppenga RH, Epstein SE. Blackwell’s Five-Minute Veterinary Consult Clinical Companion: Small Animal Toxicology. John Wiley & Sons; 2024. 980 p.

Dimascio A, Greenblatt M, Hyde RW. A study of the effects of L.S.D.: physiologic and psycho- logical changes and their interrelations. AJP. 1957 Oct;114(4):309-17. doi:10.1176/ajp.114.4.309

Forrer GR, Goldner RD. Experimental physiological studies with lysergic acid diethyl- amide (LSD-25). AMA Arch Neurol Psychiatry. 1951 May;65(5):581-8. doi:10.1001/arch- neurpsyc.1951.02320050038004 PubMed PMID: 14818479.

Leuner H. Die experimentelle Psychose. [The experimental psychosis.]. Oxford, England: Springer-Verlag; 1962. 275 p. (Die experimentelle Psychose). doi:10.1007/978-3-642-86258-8

Liddell DW, Weil-Malherbe H. The effects of methedrine and of lysergic acid diethylamide on mental processes and on the blood adrenaline level. J Neurol Neurosurg Psychiatry. 1953 Feb;16(1):7-13. doi:10.1136/jnnp.16.1.7 PubMed PMID: 13023434; PubMed Central PMCID: PMC503108.

Savage C. Lysergic acid diethylamide (LSD-25): a clinical-psychological study. AJP. 1952 Jun;108(12):896-900. doi:10.1176/ajp.108.12.896

Hensala JD, Epstein LJ, Blacker KH. LSD and psychiatric inpatients. Arch Gen Psychiatry. 1967 May;16(5):554-9. doi:10.1001/archpsyc.1967.01730230038005 PubMed PMID: 6023945.

Matthew H. Lysergic acid diethylamide intoxication. Br Med J. 1968 Feb 10;1(5588):380-380. doi:10.1136/bmj.1.5588.380 PubMed PMID: 5638269.

Liechti ME. Modern Clinical Research on LSD. Neuropsychopharmacol. 2017 Oct;42(11):2114- 27. doi:10.1038/npp.2017.86

Preller K, Herdener M, Pokorny T, Planzer A, Krähenmann R, Staempfli P, et al. The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Current Biology. 2017 Jan 26;27. doi:10.1016/j.cub.2016.12.030

Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psy- choactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016 Aug;26(8):1327-37. doi:10.1016/j.euroneuro.2016.05.001 PubMed PMID: 27216487.

Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neurore- port. 1998 Dec 1;9(17):3897-902. doi:10.1097/00001756-199812010-00024 PubMed PMID: 9875725.

Family N, Hendricks PS, Williams LT, Luke D, Krediet E, Maillet EL, et al. Safety, tolerabili- ty, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study. J Psychopharmacol. 2022 Mar;36(3):321-36. doi:10.1177/02698811211069103 PubMed PMID: 35253516.

Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, et al. Safe- ty, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethyl- amide (LSD) in healthy older volunteers. Psychopharmacology (Berl). 2020 Mar;237(3):841- 53. doi:10.1007/s00213-019-05417-7 PubMed PMID: 31853557; PubMed Central PMCID: PMC7036065.

Grumann C, Henkel K, Brandt SD, Stratford A, Passie T, Auwärter V. Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration. Drug Test Anal. 2020 Aug;12(8):1144-53. doi:10.1002/dta.2821 PubMed PMID: 32415750.

Holze F, Duthaler U, Vizeli P, Müller F, Borgwardt S, Liechti ME. Pharmacokinetics and sub- jective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharmacol. 2019 Jul;85(7):1474-83. doi:10.1111/bcp.13918 PubMed PMID: 30883864; PubMed Central PM- CID: PMC6595343.

Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, et al. Pharmacokinet- ics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects. Clin Pharma- cokinet. 2017 Oct;56(10):1219-30. doi:10.1007/s40262-017-0513-9 PubMed PMID: 28197931; PubMed Central PMCID: PMC5591798.

Aghajanian GK, Bing OH. Persistence of lysergic acid diethylamide in the plasma of human subjects. Clin Pharmacol Ther. 1964;5:611-4. doi:10.1002/cpt196455611. PubMed PMID: 14209776.

Upshall DG, Wailling DG. The determination of LSD in human plasma following oral admin- istration. Clin Chim Acta. 1972 Jan;36(1):67-73. doi:10.1016/0009-8981(72)90159-3 PubMed PMID: 5007719.

Libânio Osório Marta RF. Metabolism of lysergic acid diethylamide (LSD): an update. Drug Metab Rev. 2019 Aug;51(3):378-87. doi:10.1080/03602532.2019.1638931 PubMed PMID: 31266388.

Barnes DT. The uses and abuses of L.S.D. and other hallucinogenic drugs. Aust N Z J Psychiatry. 1970 Dec;4(4):170-3. doi:10.3109/00048677009159331 PubMed PMID: 5286778.

Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, et al. Sur- vey study of challenging experiences after ingesting psilocybin mushrooms: Acute and en- during positive and negative consequences. J Psychopharmacol. 2016 Dec;30(12):1268- 78. doi:10.1177/0269881116662634 PubMed PMID: 27578767; PubMed Central PMCID: PMC5551678.

Grinspoon L, Bakalar JB. Psychedelic Drugs Reconsidered. Lindesmith Center; 1997. 385 p.

Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:250-8. doi:10.1016/j.pnpbp.2015.03.002 PubMed PMID: 25784600.

Gable RS. Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. Am J Drug Alcohol Abuse. 1993;19(3):263-81. doi:10.3109/00952999309001618 PubMed PMID: 8213692.

Strassman RJ. Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis. 1984 Oct;172(10):577-95. doi:10.1097/00005053-198410000-00001 PubMed PMID: 6384428.

Morgan CJA, Noronha LA, Muetzelfeldt M, Feilding A, Curran HV. Harms and benefits as- sociated with psychoactive drugs: findings of an international survey of active drug users. J Psychopharmacol. 2013 Jun;27(6):497-506. doi:10.1177/0269881113477744 PubMed PMID: 23438502; PubMed Central PMCID: PMC4107777.

Nutt DJ, King LA, Phillips LD, Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010 Nov 6;376(9752):1558-65. doi:10.1016/ S0140-6736(10)61462-6 PubMed PMID: 21036393.

van Amsterdam J, Nutt D, Phillips L, van den Brink W. European rating of drug harms. J Psychopharmacol. 2015 Jun;29(6):655-60. doi:10.1177/0269881115581980 PubMed PMID: 25922421.

van Amsterdam J, Pennings E, Brunt T, van den Brink W. Physical harm due to chronic sub- stance use. Regul Toxicol Pharmacol. 2013 Jun;66(1):83-7. doi:10.1016/j.yrtph.2013.03.007 PubMed PMID: 23542091.

van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol. 2011 Apr;59(3):423-9. doi:10.1016/j.yrtph.2011.01.006 PubMed PMID: 21256914.

Bruhn JG, De Smet PAGM, El-Seedi HR, Beck O. Mescaline use for 5700 years. Lancet. 2002 May 25;359(9320):1866. doi:10.1016/S0140-6736(02)08701-9 PubMed PMID: 12044415.

Cassels BK, Sáez-Briones P. Dark Classics in Chemical Neuroscience: Mescaline. ACS Chem Neurosci. 2018 Oct 17;9(10):2448-58. doi:10.1021/acschemneuro.8b00215 PubMed PMID: 29847089.

El-Seedi HR, De Smet PAGM, Beck O, Possnert G, Bruhn JG. Prehistoric peyote use: alka- loid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol. 2005 Oct 3;101(1-3):238-42. doi:10.1016/j.jep.2005.04.022 PubMed PMID: 15990261.

Halberstadt AL, Powell SB, Geyer MA. Role of the 5-HT₂A receptor in the locomotor hyper- activity produced by phenylalkylamine hallucinogens in mice. Neuropharmacology. 2013 Jul;70:218-27. doi:10.1016/j.neuropharm.2013.01.014 PubMed PMID: 23376711; PubMed Central PMCID: PMC3934507.

Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG. Psychological and cog- nitive effects of long-term peyote use among Native Americans. Biol Psychiatry. 2005 Oct 15;58(8):624-31. doi:10.1016/j.biopsych.2005.06.038 PubMed PMID: 16271313.

Ogunbodede O, McCombs D, Trout K, Daley P, Terry M. New mescaline concentrations from 14 taxa/cultivars of Echinopsis spp. (Cactaceae) (“San Pedro”) and their relevance to shamanic practice. J Ethnopharmacol. 2010 Sep 15;131(2):356-62. doi:10.1016/j.jep.2010.07.021 PubMed PMID: 20637277.

Clement BA, Goff CM, Forbes TDA. Toxic amines and alkaloids from Acacia berlandieri. Phy- tochemistry. 1997 Sep 1;46(2):249-54. doi:10.1016/S0031-9422(97)00240-9

Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic As- pects of Peyote and Mescaline: Clinical and Forensic Repercussions. Curr Mol Pharmacol. 2019;12(3):184-94. doi:10.2174/1874467211666181010154139 PubMed PMID: 30318013; PubMed Central PMCID: PMC6864602.

Neal JM, Sato PT, Howald WN, McLaughlin JL. Peyote Alkaloids: Identification in the Mexican Cactus Pelecyphora aselliformis Ehrenberg. Science. 1972;176(4039):1131-3.

Carod-Artal FJ. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia. 2015;30(1):42-9. doi:10.1016/j.nrl.2011.07.003 PubMed PMID: 21893367.

Carod-Artal FJ, Vázquez-Cabrera CB. [Mescaline and the San Pedro cactus ritual: archaeo- logical and ethnographic evidence in northern Peru]. Rev Neurol. 2006 Apr 16;42(8):489-98. PubMed PMID: 16625512.

Sayin U. The Consumption of Psychoactive Plants in Ancient Global and Anatolian Cultures During Religious Rituals: The Roots of the Eruption of Mythological Figures and Common Sym- bols in Religions and Myths. NeuroQuantology. 2014 Jun 10;12. doi:10.14704/nq.2014.12.2.753

Heffter A. Über Cacteenalkaloide. Berichte der deutschen chemischen Gesellschaft. 2006 Jan 28;29:216-27. doi:10.1002/cber.18960290145

Späth E. Über dieAnhalonium-Alkaloide. Monatshefte für Chemie. 1919 Feb 1;40(2):129-54. doi:10.1007/BF01524590

Dyck E, Farrell P. Psychedelics and psychotherapy in Canada: Humphry Osmond and Ald- ous Huxley. Hist Psychol. 2018 Aug;21(3):240-53. doi:10.1037/hop0000088 PubMed PMID: 30138029.

Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV. Psychedelic Drugs in Bio- medicine. Trends Pharmacol Sci. 2017 Nov;38(11):992-1005. doi:10.1016/j.tips.2017.08.003 PubMed PMID: 28947075.

Nichols DE. Studies of the relationship between molecular structure and hallucinogenic ac- tivity. Pharmacol Biochem Behav. 1986 Feb;24(2):335-40. doi:10.1016/0091-3057(86)90362-x PubMed PMID: 3952123.

Patel AR. Mescaline and related compounds. Fortschr Arzneimittelforsch. 1968;11:11-47. doi:10.1007/978-3-0348-7062-7_1 PubMed PMID: 4873202.

Freedman DX. The psychopharmacology of hallucinogenic agents. Annu Rev Med. 1969;20:409- 18. doi:10.1146/annurev.me.20.020169.002205 PubMed PMID: 4894506.

Guttmann E. Artificial Psychoses Produced by Mescaline. Journal of Mental Science. 1936 May;82(338):203-21. doi:10.1192/bjp.82.338.203

Kovacic P, Somanathan R. Novel, unifying mechanism for mescaline in the central nervous sys- tem: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships. Oxid Med Cell Longev. 2009;2(4):181-90. doi:10.4161/oxim.2.4.9380 PubMed PMID: 20716904; PubMed Central PMCID: PMC2763256.Hardman HF, Haavik CO, Seevers MH. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol. 1973 Jun;25(2):299-309. doi:10.1016/s0041-008x(73)80016-x PubMed PMID: 4197635.

Kapadia GJ, Fayez MB. Peyote constituents: chemistry, biogenesis, and biological effects. J Pharm Sci. 1970 Dec;59(12):1699-727. doi:10.1002/jps.2600591202 PubMed PMID: 5499699.

Schultes RE. Hallucinogens of plant origin. Science. 1969 Jan 17;163(3864):245-54. doi:10.1126/ science.163.3864.245 PubMed PMID: 4883616.

Olive MF. Peyote And Mescaline. 1st edition. Chelsea House Pub; 2007.

Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology. 1999 Aug;21(2 Suppl):16S-23S. doi:10.1016/S0893-133X(98)00135-3 PubMed PMID: 10432484.

Monte AP, Waldman SR, Marona-Lewicka D, Wainscott DB, Nelson DL, Sanders-Bush E, et al. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem. 1997 Sep 12;40(19):2997-3008. doi:10.1021/jm970219x PubMed PMID: 9301661.

Freedman DX, Gottlieb R, Lovell RA. Psychotomimetic drugs and brain 5-hydroxytrypt- amine metabolism. Biochemical Pharmacology. 1970 Mar 1;19:1181-8. doi:10.1016/0006- 2952(70)90378-3

Tilson HA, Sparber SB. Studies on the concurrent behavioral and neurochemical effects of psy- choactive drugs using the push-pull cannula. J Pharmacol Exp Ther. 1972 Jun;181(3):387-98. PubMed PMID: 5033008.

Kyzar EJ, Collins C, Gaikwad S, Green J, Roth A, Monnig L, et al. Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology. Prog Neuropsy- chopharmacol Biol Psychiatry. 2012 Apr 27;37(1):194-202. doi:10.1016/j.pnpbp.2012.01.003 PubMed PMID: 22251567; PubMed Central PMCID: PMC3294104.

Pálenícek T, Balíková M, Bubeníková-Valesová V, Horácek J. Mescaline effects on rat behav- ior and its time profile in serum and brain tissue after a single subcutaneous dose. Psycho- pharmacology (Berl). 2008 Jan;196(1):51-62. doi:10.1007/s00213-007-0926-5 PubMed PMID: 17922234.

Trulson ME, Crisp T, Henderson LJ. Mescaline elicits behavioral effects in cats by an ac- tion at both serotonin and dopamine receptors. Eur J Pharmacol. 1983 Dec 9;96(1-2):151-4. doi:10.1016/0014-2999(83)90544-7 PubMed PMID: 6581976.

Dasgupta A. Chapter Five - Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse. In: Makowski GS, ed- itor. Advances in Clinical Chemistry [Internet]. Elsevier; 2017 [cited 2025 Mar 18]. p. 163-86. Available from: https://www.sciencedirect.com/science/article/pii/S0065242316300555 doi:10.1016/bs.acc.2016.07.004

Mokrasch LC, Stevenson I. The metabolism of mescaline with a note on correlations be- tween metabolism and psychological effects. J Nerv Ment Dis. 1959 Aug;129:177-83. doi:10.1097/00005053-195908000-00007 PubMed PMID: 14423321.

Cochin J, Woods LA, Seevers MH. The absorption, distribution and urinary excretion of mes- caline in the dog. J Pharmacol Exp Ther. 1951 Feb;101(2):205-9. PubMed PMID: 14814616.

Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacology & therapeutics. 2004;102(2):131-8.

Charalampous KD, Walker KE, Kinross-Wright J. Metabolic fate of mescaline in man. Psycho- pharmacologia. 1966;9(1):48-63. doi:10.1007/BF00427703 PubMed PMID: 5989103.

Harley-Mason J, Laird AH, Smythies JR. (I) The Metabolism of Mescalin in the Human (II) Delayed Clinical Reactions to Mescalin. Stereotactic and Functional Neurosurgery. 1958;18(2- 4):152-5.

Shah NS, Green C. Tissue levels of mescaline in mice: influence of chlorpromazine on repeat- ed administration of mescaline. Eur J Pharmacol. 1973 Dec;24(3):334-40. doi:10.1016/0014- 2999(73)90159-3 PubMed PMID: 4766694.

Jensen O, Rafehi M, Gebauer L, Brockmöller J. Cellular Uptake of Psychostimulants - Are High- and Low-Affinity Organic Cation Transporters Drug Traffickers? Front Pharmacol. 2020;11:609811. doi:10.3389/fphar.2020.609811 PubMed PMID: 33551812; PubMed Central PMCID: PMC7854383.

Seiler N, Demisch L. Oxidative metabolism of mescaline in the central nervous system. 3. Side chain degradation of mescaline and formation of 3,4,5-trimethoxy-benzoic acid in vivo. Biochem Pharmacol. 1974 Jan 15;23(2):259-71. doi:10.1016/0006-2952(74)90417-1 PubMed PMID: 4813343.

Daly J, Axelrod J, Witkop B. Methylation and demethylation in relation to the in vitro metab- olism of mescaline. Ann N Y Acad Sci. 1962 Jan 13;96:37-43. doi:10.1111/j.1749-6632.1962. tb50099.x PubMed PMID: 13883261.

Carstairs SD, Cantrell FL. Peyote and mescaline exposures: a 12-year review of a statewide poison center database. Clin Toxicol (Phila). 2010 May;48(4):350-3. doi:10.3109/15563650903586745 PubMed PMID: 20170392.

Gołembiowska K, Jurczak A, Kamińska K, Noworyta-Sokołowska K, Górska A. Effect of Some Psychoactive Drugs Used as “Legal Highs” on Brain Neurotransmitters. Neurotox Res. 2016 Apr;29(3):394-407. doi:10.1007/s12640-015-9569-1 PubMed PMID: 26501352; PubMed Cen- tral PMCID: PMC4786600.

SCHULTES R. The appeal of peyote (Lophophora williamsii) as a medicine. American An- thropologist, 40, 698-715. American Anthropologist. 2009 Oct 28;40:698-715. doi:10.1525/ aa.1938.40.4.02a00100

McLaughlin JL. Peyote: an introduction. Lloydia. 1973 Mar;36(1):1-8. PubMed PMID: 4576311.

Halpern J. The Use of Hallucinogens in the Treatment of Addiction. Addiction Research & Theory. 2009 Jul 11;4:177-89. doi:10.3109/16066359609010756

Gilmore HT. Peyote use during pregnancy. S D J Med. 2001 Jan;54(1):27-9. PubMed PMID: 11211421.

Benko J, Vranková S. Natural Psychoplastogens As Antidepressant Agents. Molecules. 2020 Mar 5;25(5):1172. doi:10.3390/molecules25051172 PubMed PMID: 32150976; PubMed Cen- tral PMCID: PMC7179157.

Geiger HA, Wurst MG, Daniels RN. DARK Classics in Chemical Neuroscience: Psilocybin. ACS Chem Neurosci. 2018 Oct 17;9(10):2438-47. doi:10.1021/acschemneuro.8b00186 PubMed PMID: 29956917.

Araújo AM, Carvalho F, Bastos M de L, Guedes de Pinho P, Carvalho M. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol. 2015 Aug;89(8):1151-73. doi:10.1007/ s00204-015-1513-x PubMed PMID: 25877327.

Lee JW, Park MS, Park JH, Cho Y, Kim C, Kim CS, et al. Taxonomic Study of the Genus Pholiota (Strophariaceae, Basidiomycota) in Korea. Mycobiology. 2020 Oct 22;48(6):476-83. doi:10.108 0/12298093.2020.1831427 PubMed PMID: 33312014; PubMed Central PMCID: PMC7717605.

Dörner S, Rogge K, Fricke J, Schäfer T, Wurlitzer JM, Gressler M, et al. Genetic Survey of Psilocybe Natural Products. Chembiochem. 2022 Jul 19;23(14):e202200249. doi:10.1002/ cbic.202200249 PubMed PMID: 35583969; PubMed Central PMCID: PMC9400892.

Guzmán G. Hallucinogenic Mushrooms in Mexico: An Overview. Economic Botany. 2008 Nov 1;62:404-12. doi:10.1007/s12231-008-9033-8

Van Court RC, Wiseman MS, Meyer KW, Ballhorn DJ, Amses KR, Slot JC, et al. Diversity, bi- ology, and history of psilocybin-containing fungi: Suggestions for research and technological development. Fungal Biol. 2022 Apr;126(4):308-19. doi:10.1016/j.funbio.2022.01.003 PubMed PMID: 35314062.

Winkelman M. Introduction: Evidence for entheogen use in prehistory and world religions. Journal of Psychedelic Studies. 2019 Sep 13;3:1-20. doi:10.1556/2054.2019.024

Tylš F, Páleníček T, Horáček J. Psilocybin--summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014 Mar;24(3):342-56. doi:10.1016/j.euroneuro.2013.12.006 PubMed PMID: 24444771.

Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv. 1997 Jun;72(3):175-84. doi:10.1016/ s0031-6865(97)00014-9 PubMed PMID: 9204776.

Horita A, Weber LJ. Dephosphorylation of psilocybin to psilocin by alkaline phosphatase. Proc Soc Exp Biol Med. 1961 Jan;106:32-4. doi:10.3181/00379727-106-26228 PubMed PMID: 13715851.

Wolbach AB, Miner EJ, Isbell H. Comparison of psilocin with psilocybin, mescaline and LSD- 25. Psychopharmacologia. 1962;3:219-23. doi:10.1007/BF00412109 PubMed PMID: 14007905.

Troxler F, Seemann F, Hofmann A. Abwandlungsprodukte von Psilocybin und Psilocin. 2. Mit- teilung über synthetische Indolverbindungen. Helvetica Chimica Acta. 1959;42(6):2073-103. doi:10.1002/hlca.19590420638

Cole SM. New research on street drugs. New York: Nova Science Publishers; 2006. xii+292.

Barceloux DG. Psilocybin and hallucinogenic mushrooms. Medical toxicology of drug abuse: Synthesized chemicals and psychoactive plants. 2012;950-60.

Clarke EGC, Moffat AC. Clarke’s Isolation and Identification of Drugs in Pharmaceuticals, Body Fluids, and Post-mortem Material. Pharmaceutical Press; 1986. 1258 p.

Anastos N, Barnett NW, Pfeffer FM, Lewis SW. Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chro- matography. Sci Justice. 2006;46(2):91-6. doi:10.1016/S1355-0306(06)71579-9 PubMed PMID: 17002211.

Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physio- logical effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl). 2004 Mar;172(2):145-56. doi:10.1007/s00213-003-1640-6 PubMed PMID: 14615876.

Isbell H. Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychophar- macologia. 1959;1:29-38. doi:10.1007/BF00408109 PubMed PMID: 14405870.

Hollister LE. Clinical, biochemical and psychologic effects of psilocybin. Arch Int Pharmaco- dyn Ther. 1961 Feb 1;130:42-52. PubMed PMID: 13715376.

Peden NR, Pringle SD. Hallucinogenic fungi. Lancet. 1982 Feb 13;1(8268):396-7. doi:10.1016/ s0140-6736(82)91422-2 PubMed PMID: 6120373.

Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology. 1999 Jun;20(6):565-81. doi:10.1016/S0893- 133X(98)00089-X PubMed PMID: 10327426.

Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci. 2008 Sep;29(9):445-53. doi:10.1016/j.tips.2008.06.006 PubMed PMID: 19086254.

Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emis- sion tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopa- thology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997 May;16(5):357- 72. doi:10.1016/S0893-133X(96)00246-1 PubMed PMID: 9109107.

Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of in- doleamine hallucinogens. Neuropharmacology. 2011 Sep;61(3):364-81. doi:10.1016/j.neuro- pharm.2011.01.017 PubMed PMID: 21256140; PubMed Central PMCID: PMC3110631.

McKenna DJ, Repke DB, Lo L, Peroutka SJ. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology. 1990 Mar;29(3):193-8. doi:10.1016/0028-3908(90)90001-8 PubMed PMID: 2139186.

Hopf A, Eckert H. Distribution patterns of 14-C-psilocin in the brains of various animals. Act Nerv Super (Praha). 1974 Mar;16(1):64-6. PubMed PMID: 4454947.

Hasler F. Untersuchungen zur Humanpharmakokinetik von Psilocybin. Erscheinungsort nicht ermittelbar: Verlag nicht ermittelbar; 1997. 136 p.

Leuner H. Halluzinogene: psychische Grenzzustände in Forschung und Psychotherapie. Bern: Huber; 1981. 458 p.

Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological rel- evance. Drug Metab Rev. 2017 Feb;49(1):84-91. doi:10.1080/03602532.2016.1278228 PubMed PMID: 28074670.

Meyer MR, Maurer HH. Absorption, distribution, metabolism and excretion pharmacog- enomics of drugs of abuse. Pharmacogenomics. 2011 Feb;12(2):215-33. doi:10.2217/pgs.10.171 PubMed PMID: 21332315.

Zou S, Chen W. Determination of oleanolic and ursolic acids in different parts of Perilla frutescens by high-performance liquid chromatography. J Braz Chem Soc. 2008;19:1429-32. doi:https://doi.org/10.1590/S0103-50532008000700030

Manevski N, Kurkela M, Höglund C, Mauriala T, Court MH, Yli-Kauhaluoma J, et al. Glu- curonidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metab Dispos. 2010 Mar;38(3):386-95. doi:10.1124/dmd.109.031138 PubMed PMID: 20007669; PubMed Central PMCID: PMC2835393.

Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, et al. Pharmaco- kinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet. 2017 Dec;56(12):1543-54. doi:10.1007/s40262-017-0540-6 PubMed PMID: 28353056.

Abramson HA, Jarvik ME, Gorin MH, Hirsch MW. Lysergic Acid Diethylamide (LSD-25):

XVII. Tolerance Development and its Relationship to a Theory of Psychosis. The Journal of Psychology. 1956 Jan;41(1):81-105. doi:10.1080/00223980.1956.9916206

Abramson HA, Rolo A. Lysergic acid diethylamide (LSD-25). 38. Comparison with ac- tion of methysergide and psilocybin on test subjects. J Asthma Res. 1965 Sep;3(1):81-96. doi:10.3109/02770906509106904 PubMed PMID: 5318626.

Isbell H, Wolbach AB, Wikler A, Miner EJ. Cross tolerance between LSD and psilocybin. Psy- chopharmacologia. 1961 May 1;2(3):147-59. doi:10.1007/BF00407974

Trulson ME, Ross CA, Jacobs BL. Lack of tolerance to the depression of raphe unit activity by lysergic acid diethylamide. Neuropharmacology. 1977 Nov;16(11):771-4. doi:10.1016/0028- 3908(77)90135-6 PubMed PMID: 593537.

Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F. The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Halluci- nogen-Persisting Perception Disorder. A Systematic Review. Front Psychiatry. 2017 Nov 20;8:240. doi:10.3389/fpsyt.2017.00240 PubMed PMID: 29209235; PubMed Central PMCID: PMC5701998.

Jo WS, Hossain MdA, Park SC. Toxicological Profiles of Poisonous, Edible, and Medicinal Mushrooms. Mycobiology. 2014 Sep;42(3):215-20. doi:10.5941/MYCO.2014.42.3.215 PubMed PMID: 25346597; PubMed Central PMCID: PMC4206786.

Meldrum BS, Naquet R. Effects of psilocybin, dimethyltryptamine, mescaline and various ly- sergic acid derivatives on the EEG and on photically induced epilepsy in the baboon (Papio papio). Electroencephalogr Clin Neurophysiol. 1971 Dec;31(6):563-72. doi:10.1016/0013- 4694(71)90072-1 PubMed PMID: 4111479.

Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS. Goldfrank’s Tox- icologic Emergencies. MCGRAW HILL; 2019.

Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, et al. 5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. BioMed Research International. 2015 Feb 1;2015. doi:10.1155/2015/438403

Löfdahl A, Rydell-Törmänen K, Müller C, Martina Holst C, Thiman L, Ekström G, et al. 5-HT2B receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo. Physiol Rep. 2016 Aug;4(15):e12873. doi:10.14814/phy2.12873 PubMed PMID: 27482070; PubMed Central PMCID: PMC4985542.

Fujimoto Y, Funao T, Suehiro K, Takahashi R, Mori T, Nishikawa K. Brain serotonin con- tent regulates the manifestation of tramadol-induced seizures in rats: disparity between tra- madol-induced seizure and serotonin syndrome. Anesthesiology. 2015 Jan;122(1):178-89. doi:10.1097/ALN.0000000000000434 PubMed PMID: 25208083.

McKenna DJ, Towers GH, Abbott F. Monoamine oxidase inhibitors in South American hallu- cinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. J Ethnopharmacol. 1984 Apr;10(2):195-223. doi:10.1016/0378-8741(84)90003-5 PubMed PMID: 6587171.

Temple JL, Bernard C, Lipshultz SE, Czachor JD, Westphal JA, Mestre MA. The Safety of In- gested Caffeine: A Comprehensive Review. Front Psychiatry. 2017 May 26;8:80. doi:10.3389/ fpsyt.2017.00080 PubMed PMID: 28603504; PubMed Central PMCID: PMC5445139.

Carey JL, Babu KM. Hallucinogens. In: Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR, editors. Goldfrank’s Toxicologic Emergencies [Internet]. 10th ed. New York, NY: McGraw-Hill Education; 2015 [cited 2025 Mar 19]. Available from: accessemergencymedicine. mhmedical.com/content.aspx?aid=1108432969

Carlini EA. Plants and the central nervous system. Pharmacol Biochem Behav. 2003 Jun;75(3):501-12. doi:10.1016/s0091-3057(03)00112-6 PubMed PMID: 12895668.

Christian ST, Harrison R, Quayle E, Pagel J, Monti J. The in vitro identification of dimethyl- tryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neu- roregulatory agent. Biochem Med. 1977 Oct;18(2):164-83. doi:10.1016/0006-2944(77)90088-6 PubMed PMID: 20877.

Barker SA, Borjigin J, Lomnicka I, Strassman R. LC/MS/MS analysis of the endogenous di- methyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate. Biomed Chromatogr. 2013 Dec;27(12):1690-700. doi:10.1002/bmc.2981 PubMed PMID: 23881860.

Barker SA, McIlhenny EH, Strassman R. A critical review of reports of endogenous psyche- delic N, N-dimethyltryptamines in humans: 1955-2010. Drug Test Anal. 2012;4(7-8):617-35. doi:10.1002/dta.422 PubMed PMID: 22371425.

Rodrigues AV, Almeida FJ, Vieira-Coelho MA. Dimethyltryptamine: Endogenous Role and Therapeutic Potential. J Psychoactive Drugs. 2019;51(4):299-310. doi:10.1080/02791072.2019

.1602291 PubMed PMID: 31018803.

HIRSHFELD-FLORES A. DMT: The Spirit Molecule: A Doctor’s Revolutionary Research Into the Biology of Near-Death and Mystical Experiences. AJP. 2002 Aug;159(8):1448-9. doi:10.1176/appi.ajp.159.8.1448

Gillin JC, Kaplan J, Stillman R, Wyatt RJ. The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine. Am J Psychiatry. 1976 Feb;133(2):203-8. doi:10.1176/ajp.133.2.203 PubMed PMID: 1062171.

Daumann J, Wagner D, Heekeren K, Neukirch A, Thiel CM, Gouzoulis-Mayfrank E. Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol. 2010 Oct;24(10):1515-24. doi:10.1177/0269881109103227 PubMed PMID: 19304859.

Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, et al. Psy- chological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry. 2005 Nov;38(6):301-11. doi:10.1055/s-2005-916185 PubMed PMID: 16342002.

Heekeren K, Neukirch A, Daumann J, Stoll M, Obradovic M, Kovar KA, et al. Prepulse inhibi- tion of the startle reflex and its attentional modulation in the human S-ketamine and N,N-di- methyltryptamine (DMT) models of psychosis. J Psychopharmacol. 2007 May;21(3):312-20. doi:10.1177/0269881107077734 PubMed PMID: 17591658.

Dos Santos RG, Bouso JC, Hallak JEC. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. Ther Adv Psychopharmacol. 2017 Apr;7(4):141- 57. doi:10.1177/2045125316689030 PubMed PMID: 28540034; PubMed Central PMCID: PMC5433617.

Tupper KW. The globalization of ayahuasca: harm reduction or benefit maximization? Int J Drug Policy. 2008 Aug;19(4):297-303. doi:10.1016/j.drugpo.2006.11.001 PubMed PMID: 18638702.

Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull. 2016 Sep;126(Pt 1):74-88. doi:10.1016/j.brainresbull.2016.04.016 PubMed PMID: 27126737; PubMed Central PMCID: PMC5048497.

McKenna D, Riba J. New World Tryptamine Hallucinogens and the Neuroscience of Aya- huasca. Curr Top Behav Neurosci. 2015 Feb 6. doi:10.1007/7854_2015_368 PubMed PMID: 25655746.

Pachter IJ, Zacharias DE, Ribeiro O. Indole Alkaloids of Acer saccharinum (the Silver Ma- ple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis. J Org Chem. 1959 Sep;24(9):1285-7. doi:10.1021/jo01091a032

Fish MS, Johnson NM, Horning EC. Piptadenia Alkaloids. Indole Bases of P. peregrina (L.) Benth. and Related Species. J Am Chem Soc. 1955 Nov;77(22):5892-5. doi:10.1021/ja01627a034

Szara S. Dimethyltryptamin: its metabolism in man; the relation to its psychotic effect to the se- rotonin metabolism. Experientia. 1956 Nov 15;12(11):441-2. doi:10.1007/BF02157378 PubMed PMID: 13384414.

Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psycho- pharmacology (Berl). 2018;235(2):399-408. doi:10.1007/s00213-017-4771-x PubMed PMID: 29119217; PubMed Central PMCID: PMC5813086.

Johnson MW, Griffiths RR. Potential Therapeutic Effects of Psilocybin. Neurotherapeutics. 2017 Jul;14(3):734-40. doi:10.1007/s13311-017-0542-y PubMed PMID: 28585222; PubMed Central PMCID: PMC5509636.

Cameron LP, Olson DE. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT). ACS Chem Neurosci. 2018 Oct 17;9(10):2344-57. doi:10.1021/acschemneuro.8b00101 PubMed PMID: 30036036.

Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005 Oct;2(4):541-53. doi:10.1602/neurorx.2.4.541 PubMed PMID: 16489364; PubMed Central PMCID: PMC1201314.

Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, et al. Triptans in the Acute Treat- ment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015;55 Suppl 4:221-35. doi:10.1111/head.12601 PubMed PMID: 26178694.

Alonso JF, Romero S, Mañanas MÀ, Riba J. Serotonergic psychedelics temporarily modify information transfer in humans. Int J Neuropsychopharmacol. 2015 Mar 28;18(8):pyv039. doi:10.1093/ijnp/pyv039 PubMed PMID: 25820842; PubMed Central PMCID: PMC4571623.

Bouso JC, Fábregas JM, Antonijoan RM, Rodríguez-Fornells A, Riba J. Acute effects of aya- huasca on neuropsychological performance: differences in executive function between experi- enced and occasional users. Psychopharmacology (Berl). 2013 Dec;230(3):415-24. doi:10.1007/ s00213-013-3167-9 PubMed PMID: 23793226.

Dos Santos R, Strassman R. Ayahuasca and psychosis. In. 2011. p. 97-9.

Pic-Taylor A, da Motta LG, de Morais JA, Junior WM, Santos A de FA, Campos LA, et al. Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psycho- tria viridis) in female Wistar rat. Behav Processes. 2015 Sep;118:102-10. doi:10.1016/j.bep- roc.2015.05.004 PubMed PMID: 26049017.

Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A, Ribeiro S, Sanches R, Crippa JAS, et al. Long-term use of psychedelic drugs is associated with differences in brain structure and per- sonality in humans. Eur Neuropsychopharmacol. 2015 Apr;25(4):483-92. doi:10.1016/j.euro- neuro.2015.01.008 PubMed PMID: 25637267.

Strassman RJ, Qualls CR, Berg LM. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry. 1996 May 1;39(9):784-95. doi:10.1016/0006-3223(95)00200-6 PubMed PMID: 8731519.

Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Human pharmacology of aya- huasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003 Jul;306(1):73-83. doi:10.1124/jpet.103.049882 PubMed PMID: 12660312.

Riba J, Rodríguez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, et al. Subjec- tive effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl). 2001 Feb;154(1):85-95. doi:10.1007/s002130000606 PubMed PMID: 11292011.

Domínguez-Clavé E, Soler J, Elices M, Pascual JC, Álvarez E, de la Fuente Revenga M, et al. Aya- huasca: Pharmacology, neuroscience and therapeutic potential. Brain Res Bull. 2016 Sep;126(Pt 1):89-101. doi:10.1016/j.brainresbull.2016.03.002 PubMed PMID: 26976063.

Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The Halluci- nogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator. Sci- ence. 2009 Feb 13;323(5916):934-7. doi:10.1126/science.1166127 PubMed PMID: 19213917; PubMed Central PMCID: PMC2947205.

Freedland CS, Mansbach RS. Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture. Drug Alcohol Depend. 1999 May 3;54(3):183-94. doi:10.1016/ s0376-8716(98)00154-9 PubMed PMID: 10372792.

Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecu- lar targets for known drugs. Nature. 2009 Nov 12;462(7270):175-81. doi:10.1038/nature08506 PubMed PMID: 19881490; PubMed Central PMCID: PMC2784146.

Riba J, McIlhenny EH, Valle M, Bouso JC, Barker SA. Metabolism and disposition of N,N-di- methyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Test Anal. 2012;4(7-8):610-6. doi:10.1002/dta.1344 PubMed PMID: 22514127.

Carbonaro TM, Eshleman AJ, Forster MJ, Cheng K, Rice KC, Gatch MB. The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-di- methyltryptamine and N,N-diisopropyltryptamine in rats and mice. Psychopharmacology (Berl). 2015 Jan;232(1):275-84. doi:10.1007/s00213-014-3658-3 PubMed PMID: 24985890; PubMed Central PMCID: PMC4282596.

Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, et al. Amphet- amine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001 Dec;60(6):1181-8. doi:10.1124/mol.60.6.1181 PubMed PMID: 11723224.

Premont RT, Gainetdinov RR, Caron MG. Following the trace of elusive amines. Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9474-5. doi:10.1073/pnas.181356198 PubMed PMID: 11504935; PubMed Central PMCID: PMC55475.

Tittarelli R, Mannocchi G, Pantano F, Romolo FS. Recreational use, analysis and tox- icity of tryptamines. Curr Neuropharmacol. 2015 Jan;13(1):26-46. doi:10.2174/157015 9X13666141210222409 PubMed PMID: 26074742; PubMed Central PMCID: PMC4462041.

Schenberg EE. Ayahuasca and cancer treatment. SAGE Open Medicine. 2013 Jan 1;1:2050312113508389. doi:10.1177/2050312113508389

Kaplan J, Mandel LR, Stillman R, Walker RW, VandenHeuvel WJ, Gillin JC, et al. Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects. Psychopharmacologia. 1974;38(3):239-45. doi:10.1007/BF00421376 PubMed PMID: 4607811.

Cohen I, Vogel WH. Determination and physiological disposition of dimethyltryptamine and diethyltryptamine in rat brain, liver and plasma. Biochem Pharmacol. 1972 Apr 15;21(8):1214- 6. doi:10.1016/0006-2952(72)90119-0 PubMed PMID: 5034205.

Takahashi T, Takahashi K, Ido T, Yanai K, Iwata R, Ishiwata K, et al. 11C-labelling of indole- alkylamine alkaloids and the comparative study of their tissue distributions. The International journal of applied radiation and isotopes. 1985;36(12):965-9.

Yanai K, Ido T, Ishiwata K, Hatazawa J, Takahashi T, Iwata R, et al. In vivo kinetics and displace- ment study of a carbon-11-labeled hallucinogen, N,N-[11C]dimethyltryptamine. Eur J Nucl Med. 1986;12(3):141-6. doi:10.1007/BF00276707 PubMed PMID: 3489620.

Sangiah S, Gomez MV, Domino EF. Accumulation of N,N-dimethyltryptamine in rat brain cortical slices. Biol Psychiatry. 1979 Dec;14(6):925-36. PubMed PMID: 41604.

Barker SA, Monti JA, Christian ST. N, N-dimethyltryptamine: an endogenous hallucinogen. Int Rev Neurobiol. 1981;22:83-110. doi:10.1016/s0074-7742(08)60291-3 PubMed PMID: 6792104.

Sitaram BR, Lockett L, Talomsin R, Blackman GL, McLeod WR. In vivo metabolism of 5-me- thoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat. Biochem Pharmacol. 1987 May 1;36(9):1509-12. doi:10.1016/0006-2952(87)90118-3 PubMed PMID: 3472526.

Barker SA, Monti JA, Christian ST. Metabolism of the hallucinogen N,N-dimethyltryptamine in rat brain homogenates. Biochem Pharmacol. 1980 Apr 1;29(7):1049-57. doi:10.1016/0006- 2952(80)90169-0 PubMed PMID: 6770869.

Gable RS. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala al- kaloids. Addiction. 2007 Jan;102(1):24-34. doi:10.1111/j.1360-0443.2006.01652.x PubMed PMID: 17207120.

Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threaten- ing diseases. J Nerv Ment Dis. 2014 Jul;202(7):513-20. doi:10.1097/NMD.0000000000000113 PubMed PMID: 24594678; PubMed Central PMCID: PMC4086777.

Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psycho- pharmacol. 2015 Jan;29(1):57-68. doi:10.1177/0269881114555249 PubMed PMID: 25389218.

Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening dis- ease: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:1-10. doi:10.1016/j.pnpbp.2017.09.012 PubMed PMID: 28947181.

Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry. 2018 Aug;30(4):317-30. doi:10.1080/09540261.2018.1482261 PubMed PMID: 30102082.

Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psi- locybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016 Dec;30(12):1181-97. doi:10.1177/0269881116675513 PubMed PMID: 27909165; PubMed Central PMCID: PMC5367557.

Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011 Jan;68(1):71-8. doi:10.1001/archgenpsychiatry.2010.116 PubMed PMID: 20819978.

Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threat- ening cancer: a randomized controlled trial. J Psychopharmacol. 2016 Dec;30(12):1165- 80. doi:10.1177/0269881116675512 PubMed PMID: 27909164; PubMed Central PMCID: PMC5367551.

Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR. Clomipramine in obsessive-com- pulsive disorder. Further evidence for a serotonergic mechanism of action. Arch Gen Psychia- try. 1989 Jan;46(1):23-8. doi:10.1001/archpsyc.1989.01810010025004 PubMed PMID: 2910220.

Jackson DD. LSD and the new beginning. J Nerv Ment Dis. 1962 Nov;135:435-9. PubMed PMID: 13957197.

Brandrup E, Vanggaard T. LSD treatment in a severe case of compulsive neurosis. Acta Psy- chiatr Scand. 1977 Feb;55(2):127-41. doi:10.1111/j.1600-0447.1977.tb00149.x PubMed PMID: 842386.

Abuzzahab FS, Anderson BJ. A review of LSD treatment in alcoholism. Int Pharmacopsychia- try. 1971;6(4):223-35. doi:10.1159/000468273 PubMed PMID: 4950565.

Dyck E. ‘Hitting Highs at Rock Bottom’: LSD Treatment for Alcoholism, 1950-1970. Social History of Medicine. 2006 Aug 1;19(2):313-29. doi:10.1093/shm/hkl039

Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research. J Psychoactive Drugs. 1998;30(4):381-418. doi:10.1080/02791072.1998.10399714 PubMed PMID: 9924844.

Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-anal- ysis of randomized controlled trials. J Psychopharmacol. 2012 Jul;26(7):994-1002. doi:10.1177/0269881112439253 PubMed PMID: 22406913.

Bowen WT, Soskin RA, Chotlos JW. Lysergic acid diethylamide as a variable in the hos- pital treatment of alcoholism: a follow-up study. J Nerv Ment Dis. 1970 Feb;150(2):111-8. doi:10.1097/00005053-197002000-00003 PubMed PMID: 4906920.

Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics. Am J Psychiatry. 1969 Apr;125(10):1352-7. doi:10.1176/ ajp.125.10.1352 PubMed PMID: 4886242.

Ludwig A, Levine J, Stark L, Lazar R. A clinical study of LSD treatment in alcoholism. Am J Psychiatry. 1969 Jul;126(1):59-69. doi:10.1176/ajp.126.1.59 PubMed PMID: 5798383.

Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970 Jun 15;212(11):1856-63. PubMed PMID: 5467681.

Smart RG, Storm T, Baker EF, Solursh L. A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Q J Stud Alcohol. 1966 Sep;27(3):469-82. PubMed PMID: 5970697.

Tomsovic M, Edwards RV. Lysergide treatment of schizophrenic and nonschizophrenic al- coholics: a controlled evaluation. Q J Stud Alcohol. 1970 Dec;31(4):932-49. PubMed PMID: 5490826.

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilo- cybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015 Mar;29(3):289-99. doi:10.1177/0269881114565144 PubMed PMID: 25586396.

Ludwig AM, Levine J. A controlled comparison of five brief treatment techniques employing LSD, hypnosis, and psychotherapy. Am J Psychother. 1965 Jul;19:417-35. doi:10.1176/appi.psy- chotherapy.1965.19.3.417. PubMed PMID: 14339608.

Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic ad- dict. A controlled study. Arch Gen Psychiatry. 1973 Jun;28(6):808-14. doi:10.1001/arch- psyc.1973.01750360040005 PubMed PMID: 4575166.

Burdick BV, Adinoff B. A proposal to evaluate mechanistic efficacy of hallucinogens in addic- tion treatment. Am J Drug Alcohol Abuse. 2013 Sep;39(5):291-7. doi:10.3109/00952990.2013.8 11513 PubMed PMID: 23968172.

Savage C, Fadiman J, Mogar R, Allen MH. The effects of psychedelic (LSD) therapy on val- ues, personality, and behavior. Int J Neuropsychiatry. 1966 Jun;2(3):241-54. PubMed PMID: 5961962.

Agin-Liebes G, Haas TF, Lancelotta R, Uthaug MV, Ramaekers JG, Davis AK. Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacol Transl Sci. 2021 Apr 9;4(2):543-52. doi:10.1021/acsptsci.1c00018 PubMed PMID: 33860184; PubMed Central PMCID: PMC8033766.

Uthaug MV, Davis AK, Haas TF, Davis D, Dolan SB, Lancelotta R, et al. The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. J Psychopharmacol. 2022 Mar;36(3):309- 20. doi:10.1177/02698811211013583 PubMed PMID: 33949246; PubMed Central PMCID: PMC8902264.

Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, et al. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. Int J Mol Sci. 2023 Jan 10;24(2):1329. doi:10.3390/ijms24021329 PubMed PMID: 36674849; PubMed Central PM- CID: PMC9865175.

Baron R, Kenny D. The moderator-mediator variable distinction in social psychological re- search: Conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology. 1986 Jan 1;51:1173-82. doi:10.1037//0022-3514.51.6.1173

Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative re- view of epidemiology, therapeutics, mystical experience, and brain network function. Phar- macol Ther. 2019 May;197:83-102. doi:10.1016/j.pharmthera.2018.11.010 PubMed PMID: 30521880.

https://compasspathways.com/ [Internet]. [cited 2025 Mar 19]. COMP360 Psilocybin Therapy Study Results by Compass Pathways. Available from: https://compasspathways.com/our-work/ comp360-psilocybin-treatment-in-trd/

dos Santos RG, Hallak JEC. Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neuroscience & Biobehavioral Reviews. 2020 Jan 1;108:423-34. doi:10.1016/j.neubiorev.2019.12.001

Hanes KR. Serotonin, psilocybin, and body dysmorphic disorder: a case report. J Clin Psycho- pharmacol. 1996 Apr;16(2):188-9. doi:10.1097/00004714-199604000-00011 PubMed PMID: 8690834.

Leonard HL, Rapoport JL. Relief of obsessive-compulsive symptoms by LSD and psilocin. Am J Psychiatry. 1987 Sep;144(9):1239-40. doi:10.1176/ajp.144.9.1239b PubMed PMID: 3631327.

Moreno FA, Delgado PL. Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry. 1997 Jul;154(7):1037-8. doi:10.1176/ajp.154.7.1037b PubMed PMID: 9210762.

Wilcox JA. Psilocybin and Obsessive Compulsive Disorder. J Psychoactive Drugs. 2014;46(5):393-5. doi:10.1080/02791072.2014.963754 PubMed PMID: 25364991.

Daniel J, Haberman M. Clinical potential of psilocybin as a treatment for mental health condi- tions. Ment Health Clin. 2018 Mar 23;7(1):24-8. doi:10.9740/mhc.2017.01.024 PubMed PMID: 29955494; PubMed Central PMCID: PMC6007659.

Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocy- bin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006 Nov;67(11):1735- 40. doi:10.4088/jcp.v67n1110 PubMed PMID: 17196053.

Rydzyński Z, Cwynar S, Grzelak L, Jagiello W. Prelminary report on the experience with psychosomimetic drugs in the treatment of alcobolism. Act Nerv Super (Praha). 1968 Oct 3;10(3):273. PubMed PMID: 5702521.

Rydzyński Z, Gruszczyński W. Treatment of alcoholism with psychotomimetic drugs. A fol- low-up study. Act Nerv Super (Praha). 1978 Feb;20(1):81-2. PubMed PMID: 636792.

Bogenschutz MP, Forcehimes AA. Development of a Psychotherapeutic Model for Psilocy- bin-Assisted Treatment of Alcoholism. Journal of Humanistic Psychology. 2017 Jul 1;57(4):389- 414. doi:10.1177/0022167816673493

Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The Psychedelic Debriefing in Al- cohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Con- tent Analysis of Clinical Sessions. Front Pharmacol. 2018;9:132. doi:10.3389/fphar.2018.00132 PubMed PMID: 29515449; PubMed Central PMCID: PMC5826346.

Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, et al. Clin- ical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. Front Pharmacol. 2018;9:100. doi:10.3389/fphar.2018.00100 PubMed PMID: 29515439; PubMed Central PMCID: PMC5826237.

Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR ago- nist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014 Nov;28(11):983-92. doi:10.1177/0269881114548296 PubMed PMID: 25213996; PubMed Central PMCID: PMC4286320.

Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157-64. doi:10.2174/1874 473708666150107121331 PubMed PMID: 25563443; PubMed Central PMCID: PMC4342293.

Barbosa PCR, Giglio JS, Dalgalarrondo P. Altered states of consciousness and short-term psy- chological after-effects induced by the first time ritual use of ayahuasca in an urban context in Brazil. J Psychoactive Drugs. 2005 Jun;37(2):193-201. doi:10.1080/02791072.2005.10399801 PubMed PMID: 16149333.

Santos RG, Landeira-Fernandez J, Strassman RJ, Motta V, Cruz APM. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol. 2007 Jul 25;112(3):507-13. doi:10.1016/j.jep.2007.04.012 PubMed PMID: 17532158.

Osório F de L, Sanches RF, Macedo LR, Santos RG dos, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Braz J Psychiatry. 2015;37(1):13-20. doi:10.1590/1516-4446-2014-1496 PubMed PMID: 25806551.

Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LRH, Maia-de-Oliveira JP, Wichert- Ana L, et al. Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recur- rent Depression: A SPECT Study. J Clin Psychopharmacol. 2016 Feb;36(1):77-81. doi:10.1097/ JCP.0000000000000436 PubMed PMID: 26650973.

Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rap- id antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019 Mar;49(4):655-63. doi:10.1017/ S0033291718001356 PubMed PMID: 29903051; PubMed Central PMCID: PMC6378413.

Galvão AC de M, de Almeida RN, Silva EADS, Freire FAM, Palhano-Fontes F, Onias H, et al. Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls. Front Psychiatry. 2018;9:185. doi:10.3389/fpsyt.2018.00185 PubMed PMID: 29867608; PubMed Central PMCID: PMC5952178.

Cameron LP, Benson CJ, DeFelice BC, Fiehn O, Olson DE. Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chem Neurosci. 2019 Jul 17;10(7):3261-70. doi:10.1021/acschemneu- ro.8b00692 PubMed PMID: 30829033; PubMed Central PMCID: PMC6639775.

Savage C, Hughes MA, Mogar R. The effectiveness of psychedelic (LSD) therapy: A preliminary report. The British Journal of Social Psychiatry. 1967;2(1):59-66.

Valliant SN, Burbage SC, Pathak S, Urick BY. Pharmacists as accessible health care providers: quantifying the opportunity. J Manag Care Spec Pharm. 2022 Jan;28(1):85-90. doi:10.18553/ jmcp.2022.28.1.85 PubMed PMID: 34949110; PubMed Central PMCID: PMC8890748.

Ng R, El-Den S, Stewart V, Collins JC, Roennfeldt H, McMillan SS, et al. Pharmacist-led inter- ventions for people living with severe and persistent mental illness: A systematic review. Aust N Z J Psychiatry. 2022 Sep;56(9):1080-103. doi:10.1177/00048674211048410 PubMed PMID: 34560826.

Brandt J. A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness. Drug Sci- ence, Policy and Law. 2023 Jan 1;9:20503245231170340. doi:10.1177/20503245231170340

Nelson NR, Armistead LT, Blanchard CM, Rhoney DH. The pharmacist’s professional iden- tity: Preventing, identifying, and managing medication therapy problems as the medication specialist. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2021;4(12):1564-71. doi:10.1002/jac5.1538

Polito V, Stevenson RJ. A systematic study of microdosing psychedelics. PLoS One. 2019;14(2):e0211023. doi:10.1371/journal.pone.0211023 PubMed PMID: 30726251; PubMed Central PMCID: PMC6364961.

Kelly DV, Young S, Phillips L, Clark D. Patient attitudes regarding the role of the pharma- cist and interest in expanded pharmacist services. Can Pharm J (Ott). 2014 Jul;147(4):239- 47. doi:10.1177/1715163514535731 PubMed PMID: 25360150; PubMed Central PMCID: PMC4212442.

Bell S, McLachlan AJ, Aslani P, Whitehead P, Chen TF. Community pharmacy services to op- timise the use of medications for mental illness: a systematic review. Aust New Zealand Health Policy. 2005 Dec 7;2:29. doi:10.1186/1743-8462-2-29 PubMed PMID: 16336646; PubMed Cen- tral PMCID: PMC1345690.

Davis B, Qian J, Ngorsuraches S, Jeminiwa R, Garza KB. The clinical impact of pharmacist services on mental health collaborative teams: A systematic review. J Am Pharm Assoc (2003). 2020;60(5S):S44-53. doi:10.1016/j.japh.2020.05.006 PubMed PMID: 32600986; PubMed Cen- tral PMCID: PMC7529835.

Dole EJ, Tommasello A. Recommendations for implementing effective substance abuse education in pharmacy practice. Subst Abus. 2002 Sep;23(3 Suppl):263-71. doi:10.1080/08897070209511520 PubMed PMID: 23581000.

Fleming GF, McElnay JC, Hughes CM, Sheridan J, Strang J. The role of the community pharma- cist in drug abuse: a comparison of service provision between Northern Ireland and England/ Wales. Pharm World Sci. 2001 Feb 1;23(1):13-6. doi:10.1023/A:1011239812477

Roberts K, Hunter C. A comprehensive system of pharmaceutical care for drug misusers. Harm Reduction Journal. 2004 May 10;1(1):6. doi:10.1186/1477-7517-1-6

Sugiarto E, Leung R, Yuen J. Pharmacists’ perspectives on psilocybin in Canada. JAPhA Prac- tice Innovations. 2024 Apr 1;1(2):100003. doi:10.1016/j.japhpi.2023.100003

Rashid I, Das S. Unlocking the Therapeutic Potential of Psychedelics: Legal and Ethical Consid- erations. Jus Corpus LJ. 2023;4:291.